Published in Clin Rheumatol on January 16, 2010
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.99
A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit (2011) 0.95
Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol (2014) 0.83
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol (2015) 0.78
Pharmacotherapy: Is there a place for leflunomide in the treatment of RA? Nat Rev Rheumatol (2010) 0.75
Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One (2015) 0.75
Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol (2010) 0.75
[Off-label therapy of rheumatoid arthritis and spondyloarthritis]. Z Rheumatol (2012) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) (2004) 1.72
Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol (2004) 1.66
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol (2005) 1.23
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis (2008) 1.02
Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol (2005) 0.99
Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum (2004) 0.90
Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int (2005) 0.90
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol (2006) 0.87
Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol (2008) 0.84
Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis. Clin Exp Rheumatol (2005) 0.84
The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum (2004) 0.83
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis. Rheumatology (Oxford) (2005) 0.83
Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) (2002) 0.82
Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int (2007) 0.80
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients. Crit Care Med (2013) 2.89
Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17
Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum (2010) 1.97
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum (2004) 1.59
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Guillain-Barré syndrome following adalimumab treatment. Clin Exp Rheumatol (2012) 1.41
Percutaneous tracheostomy in patients on anticoagulants. Ann Card Anaesth (2015) 1.38
Phytothermotherapy in osteoarthritis: a randomized controlled clinical trial. J Altern Complement Med (2011) 1.38
miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol (2009) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol (2007) 1.26
Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev (2005) 1.25
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int (2010) 1.14
Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev (2007) 1.11
Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta (2012) 1.09
Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem (2009) 1.09
Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol (2010) 1.06
Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev (2012) 1.03
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis (2007) 1.02
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol (2012) 1.02
Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth (2011) 1.02
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol (2007) 0.96
Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int (2009) 0.95
Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol (2012) 0.95
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology (2014) 0.94
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost (2014) 0.93
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm (2013) 0.93
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol (2014) 0.93
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol (2013) 0.92
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol (2014) 0.91
Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol (2013) 0.91
Chromosome 17p12-q11 harbors susceptibility loci for systemic lupus erythematosus. Hum Genet (2004) 0.91
Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev (2010) 0.90
Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med (2013) 0.90
Subcutaneous panniculitis-like T-cell lymphoma misdiagnosed as lupus erythematosus panniculitis. Clin Rheumatol (2006) 0.90
Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol (2004) 0.90
Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clin Exp Rheumatol (2012) 0.90
Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol (2012) 0.89
A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. Clin Exp Rheumatol (2012) 0.89
Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med (Berl) (2008) 0.89
High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol (2013) 0.89
Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments. Ann N Y Acad Sci (2007) 0.89
Short- and long-term effects of spa therapy in knee osteoarthritis. Am J Phys Med Rehabil (2010) 0.88
Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med (2012) 0.88
Effect of hydrostatic pressure of various magnitudes on osteoarthritic chondrocytes exposed to IL-1beta. Indian J Med Res (2010) 0.88
Spa therapy: can be a valid option for treating knee osteoarthritis? Int J Biometeorol (2014) 0.87
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. J Mol Med (Berl) (2011) 0.86
Dicrocoelium dendriticum: a true infection? Infez Med (2009) 0.86
Osteogenic growth peptide effects on primary human osteoblast cultures: potential relevance for the treatment of glucocorticoid-induced osteoporosis. J Cell Biochem (2006) 0.86
Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol (2011) 0.86
From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int (2013) 0.85
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration (2005) 0.85
KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis. Pediatr Blood Cancer (2014) 0.85
Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol (2010) 0.85
Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol (2006) 0.85
Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clin Exp Rheumatol (2012) 0.85
Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs (2011) 0.85
The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev (2012) 0.84
Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J Cardiothorac Vasc Anesth (2012) 0.84
The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis (2010) 0.84
Autoinflammatory diseases and cardiovascular manifestations. Ann Med (2011) 0.84
Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med (2011) 0.84
First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One (2013) 0.83
Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis (2013) 0.83
Efficacy of balneotherapy on pain, function and quality of life in patients with osteoarthritis of the knee. Int J Biometeorol (2011) 0.83
Interleukin-1 Inhibition in Behçet's disease. Isr Med Assoc J (2016) 0.83
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol (2013) 0.82
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis (2012) 0.82
Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: more than expected? Autoimmun Rev (2009) 0.82
Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity. Arthritis Care Res (Hoboken) (2011) 0.82
Urinary neutrophil gelatinase-associated lipocalin as an early predictor of prolonged intensive care unit stay after cardiac surgery. Ann Card Anaesth (2012) 0.82
Dexmedetomidine vs midazolam as preanesthetic medication in children: a meta-analysis of randomized controlled trials. Paediatr Anaesth (2015) 0.82
HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev (2003) 0.81
Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease. Am J Cardiol (2007) 0.81
Ultrasound detection of calcium pyrophosphate dihydrate crystal deposits in menisci: a pilot in vivo and ex vivo study. Ann Rheum Dis (2012) 0.81
Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev (2009) 0.81
Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol (2014) 0.81
Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies. Ann N Y Acad Sci (2007) 0.81
Inquiry is fatal to certainty-is the ultrasonography double contour sign specific for uric acid-induced arthritis? Arthritis Rheum (2013) 0.81
Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. Medicine (Baltimore) (2015) 0.81
The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α. Eur J Immunol (2013) 0.80
Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus. J Rheumatol (2011) 0.80
Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol (2004) 0.80
Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J (2012) 0.80
Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken) (2015) 0.80
Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection. Clin Exp Rheumatol (2013) 0.80